Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...

By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...

The Swiss drugmaker Roche presented the latest data for its experimental multiple sclerosis drug, setting the stage for the ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.

Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...

A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...

Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...

Usually referred to by the shorthand name MS, the disease shows up differently in people, but often includes fatigue, problems with memory and varying degrees of mobility impairment. For a while, ...

Nearly one in five stable MS patients developed significant radiological inflammation after stopping first-line treatment. The median time to disease activity after discontinuing treatment was 12 ...